RACGP raises safety questions on new anticoagulants
In a submission to the health department’s Sansom Review of Anticoagulation Therapies in Atrial Fibrillation, the college questioned whether appropriate groundwork had been laid ahead of the launch of dabigatran and rival drugs.
“Dabigatran is a moderate-risk drug from a new drug class, and patient safety should be considered before marketing priorities,” says the submission, one of 64 posted on the PBS website.
“The RACGP believes the introduction of the drug class has been progressed before appropriate guidelines, prescribing practices (e.g. therapeutic options) and monitoring